Date:3/26/2009

uipment, net 895 209 Product rights, net 17,702 4,936 Goodwill 13,231 - Amounts due from related parties 38 29 Deposits 46 33 Total assets $69,889 $15,909 Liabilities and Stockholders' Equity (Deficit) Current liabilities: Accounts payable $10,288 $2,214 Accrued expenses 19,052 11,092 Current portion of license agreement liability 2,543 647 Line of credit - 1,750 Income taxes payable 2,937 130 Total current liabilities 34,820 15,833 Long-term liabilities: License agreement liability, less current portion 2,313 2,959 Note payable, related party - 9,412 Deferred income tax liability 3,330 - Total long-term liabilities 5,643 12,371 Total liabilities 40,463 28,204 Commitments and contingencies Stockholders' equity (deficit) Preferred stock - $0.001 par value, 5,000,000 shares authorized; no shares issued and outstanding - - Common stock - $0.001 par value, 90,000,000 shares authorized; 12,023,747 and 5,934,496 shares issued and outstanding as of December 31, 2008 and December 31, 2007, respectively 12 6 Additional paid-in capital 33,519 797 Accumulated deficit
'/>"/>

SOURCE Cornerstone Therapeutics Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related biology technology :

1. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
2. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
3. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
4. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Tuesday, March 24, 2009
5. Cell Therapeutics Announces Filing of Form 10-K
6. Horizon Therapeutics Selected to Present at InsideVentures Debut Investor Conference March 25-26, Santa Barbara, California
7. Oxygen Biotherapeutics, Inc. Expands Board of Directors
8. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
9. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
10. Nile Therapeutics Announces Information in Compliance With NASDAQ Marketplace Rule 4350 and Reiterates 2009 Objectives
11. Medarex to Present at the Needham Cancer Therapeutics Conference